Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M3PBcWN6fG:2b4jpZ{BCe3OjeR?= M3Hv[lExKG6P Mn7TO|IhcA>? M2TYd2ROW09? NUSxNJVrWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NIrPTYQzPDlyMEi3Ny=>
HT-29 NFTmSmZEgXSxdH;4bYMhSXO|YYm= M1nUXFExKG6P M4SxUFczKGh? MkmySG1UVw>? MV\Qc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? MkXkNlQ6ODB6N{O=
HT-29 M3rZU2N6fG:2b4jpZ{BCe3OjeR?= M4\SUlExKG6P M{nlcVczKGh? NVjJdVJ6TE2VTx?= MYPQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=> NGLQOXQzPDlyMEi3Ny=>
PC3 M{[zZ2tqdmG|ZTDBd5NigQ>? M121W|ExOCCwTR?= Mk\UNUBp Mmj5SG1UVw>? NXj0SYhYWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> MYCyNVk4QDZ6Mx?=
PC3 NUDH[opsU2mwYYPlJGF{e2G7 MYSxNFAhdk1? NVzPOZJ5OSCq NIPCVFFFVVOR M1jGUGRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MmjqNlE6Pzh4OEO=
PC3 M{XFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDkd3EyNjVizszN M{Xi[VEhcA>? NEPCNVJFVVOR M1zuTWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NFPXZVAzOTl5OE[4Ny=>
HEK293 NUjINVBmTnWwY4Tpc44hSXO|YYm= M3LtU|ExOCCwTR?= MlfIPEBp Mkj5SG1UVw>? MnuyTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P MVKyNVU{QTNyMR?=
BT-20 NHWw[HFMcW6jc3WgRZN{[Xl? M3f0T|IxKM7:TR?= NFHaTWhFVVOR MYPEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? MVyyNVM2OzV3MR?=
U937 MWTBcpRq[mGldHXybYFtKEG|c3H5 NF75OpU2OCEQvF2= NIDQXoM1QCCq NWTzTFZTTE2VTx?= MmrvTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| NFyxb3AzOTF2MkGwOi=>
U937 MmKyRY51cWKjY4TldolidCCDc4PhfS=> NFvybos2OCEQvF2= NY\vdnlIPDhiaB?= NIq0R5NFVVOR MXrEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{ MWCyNVE1OjFyNh?=
U937 MmHiRY51cWKjY4TldolidCCDc4PhfS=> M{C2O|UxKM7:TR?= M1jW[|Q5KGh? MXXEUXNQ Mk\DSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> NEnJblgzOTF2MkGwOi=>
MCF-7 NGDrXnhCfXSxcHjh[5khSXO|YYm= NFTRSYg{OCCwTR?= NXvoWXFsPCCq MkLESG1UVw>? NYDQU2dlUW6mdXPld{BifXSxcHjh[5k> NW\kR5dqOjByMkixN|Q>
U87MG NYm4VJRtU2mwYYPlJGF{e2G7 M3jFOlEh|ryP MWm2JIg> MUnEUXNQ MoXsVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? M1fkNlE6QDR6NEC0
U87MG NYrQZplLU2mwYYPlJGF{e2G7 M1G0T|Eh|ryP MVe2JIg> NX\2NZRRTE2VTx?= MojKVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= M3;lflE6QDR6NEC0
U87MG Ml\ET4lv[XOnIFHzd4F6 MWexJO69VQ>? NGO1[ok3KGh? MYHEUXNQ NXWxcph1TG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MoLXNVk5PDh2MES=
U87MG NFO5U5JMcW6jc3WgRZN{[Xl? MX6xJO69VQ>? Ml3TOkBp NFK2V3ZFVVOR MVPEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> MnPiNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb MoHRRZV1d3CqYXf5JGF{e2G7 NVHuN|VmOC5{IN88US=> M1nYW|I1KGh? MUfEUXNQ MlXKTY5lfWOnczDheZRweGijZ4m= NGnTRYUyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 NGW2W2pCfXSxcHjh[5khSXO|YYm= M3jjflAvOiEQvF2= MnnWNlQhcA>? M3q2UmROW09? NFjHOoNKdmS3Y3XzJIF2fG:yaHHnfS=> MXOxPFM6OTl2OR?=
H4 MmWySpVv[3Srb36gRZN{[Xl? M3[yPVAvOiEQvF2= MWiyOEBp M3SxSWROW09? M2n3cGlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> MnfqNVgxOjR3OES=
HeLa NUTNeY5pTnWwY4Tpc44hSXO|YYm= NFvyVmwyODBibl2= M{D5flM3KGh? MWDEUXNQ M1j3NWlv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MnjZNVc2PjN|OEW=
HeLa M2\FfmZ2dmO2aX;uJGF{e2G7 Mo\NNVAxKG6P MYezOkBp M2DXS2ROW09? NHjpcY9KdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? M3LpRlE4PTZ|M{i1
HeLa MWXGeY5kfGmxbjDBd5NigQ>? NH74Sm4yODBibl2= NVnDbYc4OzZiaB?= MYnEUXNQ MWDJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= M4ewS|E4PTZ|M{i1
SYF MU\GeY5kfGmxbjDBd5NigQ>? NH3mcpUyODBibl2= MVqyOEBp MUfEUXNQ MmjBTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NGrDbVIyPzV4M{O4OS=>
SYF MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfxcY8yODBibl2= NFzITmQzPCCq M1j0XmROW09? NXy5[Gh7UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> M{mwbFE4PTZ|M{i1
HEK293T M33WWWFvfGm4aYLhcEBCe3OjeR?= MY[xJI5O NYrxd2FkPCCm NYjYe2cyTE2VTx?= MoHSTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= NFXWO|EyPzR6NUWwNS=>
HEK293T MVTBcpRqfmm{YXygRZN{[Xl? MmTaNUBvVQ>? MX20JIQ> MoDZSG1UVw>? MnHlTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= NHP2WYcyPzR6NUWwNS=>
PBMC NEHOWpFHfW6ldHnvckBCe3OjeR?= MlLRNUBvVQ>? NUXtcFM6OTRiZB?= NIWzOJNFVVOR NXe5bI15WmWmdXPld{BES1J3IHTlcpNqfHl? NIC0U2MyPzR6NUWwNS=>
PBMC Mlj4SpVv[3Srb36gRZN{[Xl? NUHtRndbOSCwTR?= NF36UJMyPCCm MXzEUXNQ NYruWGVNTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? MXSxO|Q5PTVyMR?=
HEK293 cells MlHNT4lv[XOnIFHzd4F6 NHS4XG82OCCwTR?= NWPDV3k{PDVibXnu NXXOS2Z7TE2VTx?= NX7Nd4JiUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= MWWxO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MkS0SpVv[3Srb36gRZN{[Xl? NIOxPFkyODBibl2= NYLEdXRDPCCq M2j5XGROW09? M1nmN2lv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk MUSxO|EzQDJ4Mh?=
Human mixed lymphocyte M3nIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrXOUBvVQ>? MlrwSG1UVw>? NHv0OFZKSzVyPUGuOkBvVS5? MWGxOlE5PTh4NR?=
Lewis rat lymph node cells MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrR[VV{PSEQvF2= NFvkUZVFVVOR NFrMVHlKSzVyPUKuOkDPxE1? NGTTPHoyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexNEBvVQ>? M12xcVczKGh? MU\EUXNQ NEfRUZJKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N NYrzdopGOTByMkG5OFg>
MRK-nu-1 M{LXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;0TWM2OD1yLki0OUBxVQ>? NWTv[G85W0GQR1XS
OCUB-M NUXhXJcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTVwMkSgdG0> NUnLSpNUW0GQR1XS
SF539 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFzLk[gdG0> NYnwbo5{W0GQR1XS
ES4 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PXSWlEPTB;MkGuOUBxVQ>? NVjBV|hVW0GQR1XS
RL95-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W0[2lEPTB;MUC3JJBO Mn3SV2FPT0WU
LC-2-ad MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrP[4RKSzVyPUSyN{BxVQ>? NFLISm5USU6JRWK=
Daudi MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR|NDDwUS=> MYjTRW5ITVJ?
NTERA-S-cl-D1 M33od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXztS2VQUUN3ME20OFMheE1? MoP3V2FPT0WU
OS-RC-2 NGjLTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvaTFd4UUN3ME22OVIheE1? MoHkV2FPT0WU
VA-ES-BJ MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETQOWpKSzVyPUeyN{BxVQ>? NG\RXmhUSU6JRWK=
GR-ST MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfOcpR7UUN3ME24OFYheE1? MnfqV2FPT0WU
SW872 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV24NYtqUUN3ME24OFYheE1? NUC4SXlCW0GQR1XS
NOS-1 NYLwR|FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTh5MTDwUS=> NFnpeoRUSU6JRWK=
MC116 M1[5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ju[2lEPTB;OUi1JJBO M1XoUHNCVkeHUh?=
NCI-H1355 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjiclBuUUN3ME2xMlAyKG6P NUPkcnVWW0GQR1XS
RPMI-8226 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zPWmlEPTB;MT6xPUBvVQ>? NYLqXJE5W0GQR1XS
TE-15 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwM{[gcm0> M4S4[3NCVkeHUh?=
Ramos-2G6-4C10 NWfkXZprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\T[mlEPTB;MT60OkBvVQ>? MXTTRW5ITVJ?
KU812 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPTUml4UUN3ME2yMlAyKG6P Ml\ZV2FPT0WU
EW-1 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnacXljUUN3ME2yMlE4KG6P MmDwV2FPT0WU
KS-1 NFWyXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTNTWM2OD1{LkS1JI5O MWLTRW5ITVJ?
SK-LMS-1 NFexOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJwNEmgcm0> NGS3XnFUSU6JRWK=
TGBC1TKB M3rGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJwNkmgcm0> M4PjdnNCVkeHUh?=
TE-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILTW5BKSzVyPUKuO|chdk1? M2PoPXNCVkeHUh?=
ETK-1 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XDW2lEPTB;Mj64NkBvVQ>? MoXJV2FPT0WU
BE-13 NWfK[YExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJwOUmgcm0> NWrDXmR3W0GQR1XS
A3-KAW MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILNT2RKSzVyPUKuPVkhdk1? NID3WIhUSU6JRWK=
TE-10 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPlVlhlUUN3ME2zMlMhdk1? NVq2dWlNW0GQR1XS
DOHH-2 M2\KSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNwM{Wgcm0> M1\CV3NCVkeHUh?=
ES6 M2jLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\tRmlEPTB;Mz60N{BvVQ>? NUTITZZnW0GQR1XS
OPM-2 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[5[nZKSzVyPUSuNVUhdk1? MoXtV2FPT0WU
SH-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLMTWM2OD12LkO0JI5O NX;SWmNlW0GQR1XS
NB13 M2W3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzmTWM2OD12LkO2JI5O NGXCRYlUSU6JRWK=
HUTU-80 NWTHRXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;HTWM2OD12LkSyJI5O M2TFcXNCVkeHUh?=
CCRF-CEM MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTRwOUSgcm0> NX;iW2NrW0GQR1XS
TGBC24TKB NH;0XGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTVwNUGgcm0> MUTTRW5ITVJ?
697 NVPnWlVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD5[2ZGUUN3ME22MlI5KG6P NXvSVodYW0GQR1XS
J-RT3-T3-5 NFe3So1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm1b|NKSzVyPU[uOFYhdk1? M{P0RXNCVkeHUh?=
KALS-1 NEjWWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTZwNU[gcm0> NFXuWlhUSU6JRWK=
no-10 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne3TWM2OD15LkK5JI5O NHTzUG5USU6JRWK=
SK-NEP-1 NInNfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVziTFFRUUN3ME24Mlc6KG6P MnXwV2FPT0WU
L-540 NHzuWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf6N5VwUUN3ME2xNE41OiCwTR?= MYjTRW5ITVJ?
JiyoyeP-2003 NXviOGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnlSVliUUN3ME2xNE46PCCwTR?= MofWV2FPT0WU
HH MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf6U5BKSzVyPUGxMlM6KG6P MkTRV2FPT0WU
SR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;rRZlKSzVyPUGxMlQ2KG6P NYLVcokyW0GQR1XS
QIMR-WIL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\QcoVKSzVyPUGxMlg2KG6P MYDTRW5ITVJ?
A4-Fuk NXzNWnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF|LkGyJI5O MlLWV2FPT0WU
CESS NUntenN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu4TWM2OD1zMz6xN{BvVQ>? M{iyUXNCVkeHUh?=
KE-37 NWe3dHNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nxOWlEPTB;MU[uNFchdk1? MVLTRW5ITVJ?
SK-UT-1 NVm2O3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljFTWM2OD1zNj64NUBvVQ>? MkLVV2FPT0WU
SIG-M5 NUfhNlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPDTWM2OD1zNz6yOUBvVQ>? M{nJdXNCVkeHUh?=
HT NIDiVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrBb3RKSzVyPUG3MlYhdk1? M2\ZPXNCVkeHUh?=
DEL MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInwW41KSzVyPUG3Mlk6KG6P Ml7sV2FPT0WU
SK-PN-DW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PaZWlEPTB;MkCuNlMhdk1? MULTRW5ITVJ?
RPMI-8402 NYTFRnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HLUWlEPTB;MkGuO|chdk1? NVjDUHJqW0GQR1XS
RPMI-6666 NWXuN2N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfuTWM2OD1{ND60NkBvVQ>? MXvTRW5ITVJ?
NCI-H720 MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCyNI5wUUN3ME2yOU41OSCwTR?= NF3obmhUSU6JRWK=
EW-16 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{npeWlEPTB;Mk[uPFchdk1? MV\TRW5ITVJ?
BL-70 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzOdVJWUUN3ME2yPE4{QCCwTR?= M17YUXNCVkeHUh?=
SF126 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNyLkO4JI5O MX3TRW5ITVJ?
BC-1 M{S0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNzLkK2JI5O NFy1[FNUSU6JRWK=
MHH-PREB-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXzTWM2OD1|Mj60OEBvVQ>? MVfTRW5ITVJ?
A101D M2P3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzv[IxKSzVyPUOyMlYzKG6P NInlNYRUSU6JRWK=
NMC-G1 NYXxcIo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\nO|JKSzVyPUOzMlY4KG6P MlW1V2FPT0WU
LB1047-RCC MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nIVmlEPTB;M{SuOlkhdk1? NImwU3JUSU6JRWK=
EM-2 NFKxcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELtdGlKSzVyPUO4MlU{KG6P MXjTRW5ITVJ?
COLO-684 NXzoNndpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;tUmlEPTB;M{muPEBvVQ>? NF\rV41USU6JRWK=
Becker Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Ww[WlEPTB;NEGuNFUhdk1? M13zfnNCVkeHUh?=
BL-41 NEjHe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fkPWlEPTB;NEOuOlYhdk1? MljaV2FPT0WU
MDA-MB-134-VI NIfTdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2wc2NKSzVyPUS0MlAzKG6P MYnTRW5ITVJ?
L-363 M1Hwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXhTWM2OD12ND63N{BvVQ>? NEDOTJFUSU6JRWK=
ECC4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7XUnZzUUN3ME20OE44QCCwTR?= NEH6Uo9USU6JRWK=
A388 NUPOXFBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR2LkiyJI5O M{P0XHNCVkeHUh?=
HEL M2XteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP3TWM2OD12OT63PUBvVQ>? M4LwXXNCVkeHUh?=
RKO M{HjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Ta[2lEPTB;NUCuNlkhdk1? MmLVV2FPT0WU
KINGS-1 M4jkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr6TWM2OD13MT61OUBvVQ>? MWLTRW5ITVJ?
EB-3 NH3qW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\EfGlEPTB;NUKuOlchdk1? NF3rO2JUSU6JRWK=
ARH-77 MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\Xd2lEPTB;NUKuPEBvVQ>? NUDv[WVZW0GQR1XS
GCIY NYnacIhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Hh[WlEPTB;NUOuOFYhdk1? MUDTRW5ITVJ?
NCI-H1304 M1qyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPvTWM2OD13Nz6yNkBvVQ>? NF;u[IJUSU6JRWK=
KARPAS-299 M2K5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v2dWlEPTB;NkGuPFIhdk1? M2fTTHNCVkeHUh?=
IA-LM NYfBXXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTfGlEPTB;NkiuNVMhdk1? NYLtcGNHW0GQR1XS
GI-1 M4PPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PaUmlEPTB;N{CuN|khdk1? MX;TRW5ITVJ?
TE-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnDUmc{UUN3ME23O{4yPyCwTR?= NVzKNo5HW0GQR1XS
LS-411N NF65e4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTd5LkW3JI5O MWHTRW5ITVJ?
no-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTh|LkK0JI5O NUTSbGNiW0GQR1XS
MV-4-11 NGmwVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTh|LkezJI5O M1\CcnNCVkeHUh?=
BV-173 NGO1SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPEc2ZKSzVyPUizMlk4KG6P NHzv[GdUSU6JRWK=
CMK MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KwWWlEPTB;OESuNVYhdk1? MlPIV2FPT0WU
LC4-1 NEjweJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DjU2lEPTB;OE[uO|Ihdk1? M2fib3NCVkeHUh?=
COR-L279 NFjU[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXCTGRwUUN3ME24O{4zPSCwTR?= M3\oeXNCVkeHUh?=
NCI-H209 M2\scGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLVRZlKSzVyPUi3MlQyKG6P NHHjPVNUSU6JRWK=
Raji MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLkNFRKSzVyPUi5MlczKG6P M3j3dnNCVkeHUh?=
LB996-RCC NHrRdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS0TWM2OD17Mz60N{BvVQ>? NX6yTXdSW0GQR1XS
NCI-H526 NGm0bYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HwWGlEPTB;OUOuOVkhdk1? NVTHenN3W0GQR1XS
KGN M1rlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnENlZsUUN3ME25Ok4zQSCwTR?= M2rie3NCVkeHUh?=
MOLT-4 NHrHTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjESVM6UUN3ME25Ok44QSCwTR?= M2nlOnNCVkeHUh?=
PF-382 M4\TOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTl4Lke5JI5O NV\oTJVLW0GQR1XS
BC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTl7LkG4JI5O NGrMbIdUSU6JRWK=
KARPAS-422 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFyMj6wPUBvVQ>? M4jYZnNCVkeHUh?=
SBC-1 NHG3VZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\rdWlEPTB;MUC3Mlc2KG6P MoTMV2FPT0WU
LC-1F MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XuO2lEPTB;MUC4MlA2KG6P NGXLZmdUSU6JRWK=
GB-1 NXTmc|IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\lRXRKSzVyPUGwPU4xOiCwTR?= MWXTRW5ITVJ?
SNB75 NWDWZnY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHYeYFXUUN3ME2xNVkvPjlibl2= M1r0Z3NCVkeHUh?=
BB65-RCC MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLB[npZUUN3ME2xNVkvQTNibl2= NWXlZnZHW0GQR1XS
NCI-N87 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILpRXNKSzVyPUGyNU46QCCwTR?= MXzTRW5ITVJ?
IST-MEL1 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M320XmlEPTB;MUKyMlM5KG6P M4jzcHNCVkeHUh?=
HOP-62 M4rQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXrTWM2OD1zMk[uPFkhdk1? MV7TRW5ITVJ?
ACN NF7ibIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTjTWM2OD1zNE[uO|Uhdk1? M{LkT3NCVkeHUh?=
DMS-114 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF3MD62O{BvVQ>? NVniW2lPW0GQR1XS
MLMA MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXhdHRnUUN3ME2xOVkvQDhibl2= NFjzboxUSU6JRWK=
HT-144 NXP1OXp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT5T4s2UUN3ME2xOlUvPDNibl2= MWjTRW5ITVJ?
C2BBe1 M3[2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ETWM2OD1zNkeuO|Yhdk1? NGO1PZdUSU6JRWK=
L-428 M3HZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fpRWlEPTB;MUe3Mlchdk1? MYPTRW5ITVJ?
DU-4475 NFLNNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\5[mlEPTB;MUi3MlY5KG6P M2TqdXNCVkeHUh?=
CP67-MEL NHjOS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XoTWlEPTB;MUm5MlM5KG6P MWHTRW5ITVJ?
MEG-01 NVPsUlgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\lTWM2OD1{MEGuPVYhdk1? M3TyNnNCVkeHUh?=
IST-SL2 NYrSbYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7tOJJ1UUN3ME2yNFgvPjNibl2= MVLTRW5ITVJ?
ES8 NHewe49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvUR4NKSzVyPUKyOU46PCCwTR?= MWXTRW5ITVJ?
COLO-800 NV75doVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2frO2lEPTB;MkO1MlI5KG6P NUfBXlV5W0GQR1XS
MFH-ino MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT0U|NKSzVyPUKzOU45PCCwTR?= M3vjTXNCVkeHUh?=
OVCAR-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPDTWM2OD1{M{euNlQhdk1? M{TUb3NCVkeHUh?=
PSN1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;FTWM2OD1{NEKuO|Ehdk1? MW\TRW5ITVJ?
EW-12 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjJeVZKSzVyPUK0N{4yKG6P M2\IfHNCVkeHUh?=
HCC1599 MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX5[ZB[UUN3ME2yOlEvPDdibl2= MlfMV2FPT0WU
SJSA-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ5MT60OkBvVQ>? NYG2W29NW0GQR1XS
ST486 M3vNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ7Nj6xOEBvVQ>? M4nzVHNCVkeHUh?=
NOMO-1 NFi5XpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly0TWM2OD1|MECuNlEhdk1? MnjFV2FPT0WU
MN-60 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNyNT6zNkBvVQ>? NVLnWWhRW0GQR1XS
HCC1187 M{HVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2yfFZOUUN3ME2zNFcvOjVibl2= MnPMV2FPT0WU
SW982 NInuWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;HTWM2OD1|MUSuO|Uhdk1? M1\P[XNCVkeHUh?=
LB647-SCLC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHzS5NRUUN3ME2zNlgvPzFibl2= MXTTRW5ITVJ?
HC-1 NIXPT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHEU|VKSzVyPUOzOU42KG6P NFT6bYVUSU6JRWK=
EHEB M172T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN|Nz61NkBvVQ>? MlTCV2FPT0WU
TUR M1vod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHCTWM2OD1|NkOuPVUhdk1? MV3TRW5ITVJ?
LU-139 NEHROIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmeyTWM2OD1|N{iuNFIhdk1? MW\TRW5ITVJ?
NB1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33VfmlEPTB;M{i0MlQ2KG6P MkH2V2FPT0WU
BB30-HNC NHrvSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN6OD6zNkBvVQ>? NF3GcHlUSU6JRWK=
HAL-01 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LBZ2lEPTB;M{i5MlI3KG6P NFHid2hUSU6JRWK=
K5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KzN2lEPTB;NEGxMlM4KG6P NVXwZXR1W0GQR1XS
MZ2-MEL NHXBUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRzMz62OEBvVQ>? M{LlU3NCVkeHUh?=
RXF393 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7PeHhKSzVyPUSxOk41PSCwTR?= MorGV2FPT0WU
NCI-H1648 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TJfGlEPTB;NEG3MlU{KG6P NF\GRXlUSU6JRWK=
TE-12 NWP1S5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXTTWM2OD12M{SuNlYhdk1? NXXacZI6W0GQR1XS
EoL-1- MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnPXHlzUUN3ME20N|cvQThibl2= MnPFV2FPT0WU
JAR M3vtfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLEOJhKSzVyPUSzPE43OiCwTR?= NVnXV5oyW0GQR1XS
DSH1 NUXMTo1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTR3OD65NUBvVQ>? M3\BOXNCVkeHUh?=
NCI-H187 NEDsXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TQZ2lEPTB;NE[yMlgyKG6P NWD1V5RLW0GQR1XS
HCE-4 NXH0dppwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTR5Nz62OkBvVQ>? NUHnVHU4W0GQR1XS
8-MG-BA MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjxPVNuUUN3ME21PFEvPTJibl2= NYnFXJVIW0GQR1XS
KLE M4PZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjyVYQ1UUN3ME21PFUvOiCwTR?= NF7rVllUSU6JRWK=
KNS-42 NFvVb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHycGRKSzVyPUW4Ok45OSCwTR?= M{DYSXNCVkeHUh?=
MSTO-211H MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn0[JNKSzVyPU[wPU44PCCwTR?= M4nJbHNCVkeHUh?=
GDM-1 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTZzND6wPUBvVQ>? M3PLcHNCVkeHUh?=
TE-1 M33SOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;aXmlEPTB;NkS2MlEzKG6P MYXTRW5ITVJ?
BT-474 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvhdVREUUN3ME22OFcvODZibl2= MVHTRW5ITVJ?
KARPAS-45 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[5TWM2OD14NEeuOkBvVQ>? NIjkeXpUSU6JRWK=
MOLT-16 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ETWM2OD14NEeuPVMhdk1? NGrB[G5USU6JRWK=
KURAMOCHI M1nqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZ3Nz61NUBvVQ>? NUS1eWhkW0GQR1XS
K-562 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HQZmlEPTB;Nk[5MlUyKG6P Mm[wV2FPT0WU
EKVX NVH3[W9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfxNXhyUUN3ME22O|IvPzFibl2= MmPnV2FPT0WU
GAK NIPucY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTvTWM2OD14N{WuN{BvVQ>? MoDMV2FPT0WU
NCI-SNU-5 M3jIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXiOmVrUUN3ME22PVAvODFibl2= NVzXd3N3W0GQR1XS
NCI-H2126 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTd{Nj64O{BvVQ>? NIL1UnRUSU6JRWK=
CTV-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j1VWlEPTB;N{S0Mlkhdk1? MoXZV2FPT0WU
SW962 NHTFeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXZdmRKUUN3ME23OFgvPDRibl2= M1vwdnNCVkeHUh?=
MONO-MAC-6 NU[xRXloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXueIJKSzVyPUe1Ok46OyCwTR?= NIDOeZhUSU6JRWK=
NCI-H748 MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn0Z5hKSzVyPUe1PE46QSCwTR?= NILvS5VUSU6JRWK=
NCI-H524 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK0bG1KSzVyPUe4NE44OyCwTR?= Mmr1V2FPT0WU
LS-123 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfMTWM2OD15OUWuOlkhdk1? NV[5OI1oW0GQR1XS
NB7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTuTWM2OD16MUSuNVQhdk1? M{\JT3NCVkeHUh?=
LS-1034 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTh{OD65PEBvVQ>? M3XrZ3NCVkeHUh?=
TE-5 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq0TWM2OD16OEOuOVYhdk1? NXu5dWlzW0GQR1XS
A704 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLVN21KUUN3ME24PVkvOTVibl2= NYnGR2Q2W0GQR1XS
TK10 NVrMZplPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTlzNj6wN{BvVQ>? M{LyNnNCVkeHUh?=
NCI-H345 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ruRWlEPTB;OUSzMlIzKG6P NGPFUFhUSU6JRWK=
CGTH-W-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;nelZGUUN3ME25OFgvOTNibl2= MWDTRW5ITVJ?
NCI-H510A MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nIRmlEPTB;OUi1MlEzKG6P MnvWV2FPT0WU
NCI-H1963 NXXwc45jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzXZnNKSzVyPUGuNFMzQTJizszN NUHldGIzW0GQR1XS
SCC-3 M4rBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO2WllvUUN3ME2xMlA{PDF2IN88US=> NIDnVZpUSU6JRWK=
EW-11 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjIeHVKSzVyPUGuNFg4PDNizszN M{DkTXNCVkeHUh?=
CPC-N NI\MTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[4eWlEPTB;MT6wPFgh|ryP Mlq1V2FPT0WU
NCI-H1417 M{XoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrZZ5FKSzVyPUGuNVIzPiEQvF2= MkDLV2FPT0WU
DG-75 NVKxPVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrCZXFKSzVyPUGuNVYzQDVizszN MUHTRW5ITVJ?
HD-MY-Z MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LGNmlEPTB;MT6xOlQyPiEQvF2= MnvEV2FPT0WU
ATN-1 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DhNGlEPTB;MT6yOlIxQSEQvF2= NVe5UmI6W0GQR1XS
KM-H2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zPNmlEPTB;MT6yOlQxQCEQvF2= MXzTRW5ITVJ?
NCI-H2081 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjle3pKSzVyPUGuNlY3OzdizszN NV63fZVsW0GQR1XS
HL-60 M4[2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFwMk[5OVkh|ryP NGLnTGJUSU6JRWK=
DB M2rmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWwTWM2OD1zLkK3NlQzKM7:TR?= MmTLV2FPT0WU
NCI-H1522 MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Hjc2lEPTB;MT6yPFg5PyEQvF2= MnvDV2FPT0WU
AM-38 M{LJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\ZVGlEPTB;MT6zNFczKM7:TR?= NVP4XWxPW0GQR1XS
NCI-H446 NHK1blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHnU3RtUUN3ME2xMlMzOTJzIN88US=> MmHYV2FPT0WU
SU-DHL-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX6TWM2OD1zLkOyPFAyKM7:TR?= MnnsV2FPT0WU
NH-12 NF;3VYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjZeGpqUUN3ME2xMlM3Ozd2IN88US=> NELRbm9USU6JRWK=
DMS-79 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwM{[4OlYh|ryP NFfIdm5USU6JRWK=
NCI-H716 NEKyUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTFeFJKSzVyPUGuN|g6QDZizszN M13kRXNCVkeHUh?=
ML-2 NX:4NHJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[2W2lEPTB;MT60NVUzQSEQvF2= NFP5Nm5USU6JRWK=
NB10 NH[wXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf6TWM2OD1zLkS2OlMzKM7:TR?= MWDTRW5ITVJ?
ONS-76 NH\EeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;veWNKSzVyPUGuOVM2PjlizszN Mmm1V2FPT0WU
LOUCY MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PnPWlEPTB;MT61OFY2PyEQvF2= MoPCV2FPT0WU
SCLC-21H NWOxPGw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWixUlJ{UUN3ME2xMlU5PTh{IN88US=> NV2yeWFSW0GQR1XS
TGW NVvn[|Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmyd4tsUUN3ME2xMlY{QTd3IN88US=> M3XuVHNCVkeHUh?=
LXF-289 M2W3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHzbmJKSzVyPUGuO|MzPjhizszN NFvITo1USU6JRWK=
BB49-HNC NWLN[Fg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwN{O1PFYh|ryP MkPiV2FPT0WU
NCI-H747 NUjIc3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rBcWlEPTB;MT63OVM1PiEQvF2= MVLTRW5ITVJ?
LU-165 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwOES5PFYh|ryP MWDTRW5ITVJ?
OMC-1 M4nZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorQTWM2OD1zLkm1NFY3KM7:TR?= NVjzNZQ5W0GQR1XS
RCC10RGB NWG5b2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwOUW4NVch|ryP MVzTRW5ITVJ?
SW684 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFwOU[wPVkh|ryP MVjTRW5ITVJ?
TE-8 M17mW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwMEW1OVkh|ryP M4D6cHNCVkeHUh?=
SK-N-DZ MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH22RVdKSzVyPUKuNVMzPzRizszN MkjYV2FPT0WU
EVSA-T MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLYRVBHUUN3ME2yMlE4OzF3IN88US=> MknxV2FPT0WU
KASUMI-1 NHnBVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHVTWM2OD1{LkG4PFE2KM7:TR?= NILNVJBUSU6JRWK=
NKM-1 NEHyboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL2NJFrUUN3ME2yMlI2PDd{IN88US=> NGm4U5RUSU6JRWK=
CAL-148 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTYdVBKSzVyPUKuN|M3OTRizszN MXLTRW5ITVJ?
NCI-H64 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnzXG9KSzVyPUKuN|QzOzJizszN MXLTRW5ITVJ?
KNS-81-FD M4nE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDJ[GtTUUN3ME2yMlM3PjJizszN NF7P[ZlUSU6JRWK=
KM12 M2DKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXaT5BKSzVyPUKuOFA5OzlizszN M2LNZXNCVkeHUh?=
SW954 NXvSOpFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjlXWd5UUN3ME2yMlQ4Pzd7IN88US=> NUPhT3Z7W0GQR1XS
NCI-H1395 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LkWWlEPTB;Mj61NlY1PSEQvF2= M{\CW3NCVkeHUh?=
DJM-1 NWnHUoE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TKUmlEPTB;Mj62NFY{KM7:TR?= NH3tT|BUSU6JRWK=
COLO-668 NU\aenp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfyTWM2OD1{LkiyOlk2KM7:TR?= NHnUdlBUSU6JRWK=
NCI-H1436 NVq5[Ic5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLWTWM2OD1{Lki1OlE2KM7:TR?= NUXKbmNDW0GQR1XS
LB2241-RCC M1uwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD3TWM2OD1{Lki2PFM6KM7:TR?= Mn3NV2FPT0WU
GT3TKB NF:y[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr4VFdKSzVyPUKuPFkxPTVizszN MX3TRW5ITVJ?
COLO-824 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\hS2lEPTB;Mj64PVc3QCEQvF2= NV;kWWxnW0GQR1XS
ES1 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q3RmlEPTB;Mj64PVg4QSEQvF2= MknIV2FPT0WU
LB771-HNC NEnTXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHVN4tKSzVyPUKuPVA6PDZizszN MmrFV2FPT0WU
GI-ME-N MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTNwMEC5NFQh|ryP MVLTRW5ITVJ?
NALM-6 NWfBTINsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofHTWM2OD1|LkCwPVM{KM7:TR?= MYTTRW5ITVJ?
LU-134-A MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLqTWM2OD1|LkC1OFI2KM7:TR?= MXnTRW5ITVJ?
DMS-153 NGDIXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmzTWM2OD1|LkC1PFI1KM7:TR?= NYDHbHM6W0GQR1XS
MZ1-PC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwMEmwO|gh|ryP MWHTRW5ITVJ?
NCI-H1155 NWr3b5J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW1d5BKSzVyPUOuNVE3OSEQvF2= NFHZU4RUSU6JRWK=
CAS-1 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTXTWM2OD1|LkGzO|A4KM7:TR?= NX;DRYZGW0GQR1XS
D-502MG MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDPOZJKSzVyPUOuNVQ{QSEQvF2= MlfIV2FPT0WU
NCI-H2141 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy1R45KSzVyPUOuNVc1PTJizszN MXTTRW5ITVJ?
NB6 M1K2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHscI1KSzVyPUOuNVgzPTlizszN NHH0W3dUSU6JRWK=
NCCIT NXzEOG9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\IdnhGUUN3ME2zMlIyQDB7IN88US=> MV\TRW5ITVJ?
NB69 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTMV4RKSzVyPUOuN|E5QTFizszN NVK4T5g6W0GQR1XS
JVM-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT4TWM2OD1|LkO2OFM{KM7:TR?= M{HIfXNCVkeHUh?=
K052 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfuc5V6UUN3ME2zMlM4QTZ6IN88US=> MmrOV2FPT0WU
HCC2157 M1vENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Hkb2lEPTB;Mz61N|IzQCEQvF2= NEji[I1USU6JRWK=
KMOE-2 M2P6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLZdVd[UUN3ME2zMlU1OjR{IN88US=> NXjJWYp5W0GQR1XS
SF268 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jJcWlEPTB;Mz63NVU2PCEQvF2= Mlr4V2FPT0WU
CHP-126 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LhRmlEPTB;Mz63OlQ2QCEQvF2= M3;uc3NCVkeHUh?=
CP66-MEL MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL4UllzUUN3ME2zMlc6ODl2IN88US=> NIXESYtUSU6JRWK=
NCI-H69 NUfRXoNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfGfXRKSzVyPUSuNFE6OzZizszN M{XWdHNCVkeHUh?=
A253 M1XGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G4XGlEPTB;ND6wNlExOSEQvF2= MWfTRW5ITVJ?
NB14 NWjMPG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXpTWM2OD12LkGwOFc6KM7:TR?= NHPoSJJUSU6JRWK=
NCI-H1694 NFzxXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DycWlEPTB;ND6xN|EyOiEQvF2= MXPTRW5ITVJ?
NCI-H2196 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm2TWM2OD12LkG3NVY6KM7:TR?= NGTyXWlUSU6JRWK=
TE-9 M4\Lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnqVGRCUUN3ME20MlE4PTh{IN88US=> NY\zelNsW0GQR1XS
D-283MED MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwMUi4OEDPxE1? MVnTRW5ITVJ?
OCI-AML2 NHzoXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjE[FBHUUN3ME20MlE6PDh7IN88US=> NF;sWItUSU6JRWK=
D-263MG Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETYVotKSzVyPUSuNlI6PjFizszN NF\jRmxUSU6JRWK=
MPP-89 NXKyfmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXC[nZXUUN3ME20MlI4OzB2IN88US=> M3rGXHNCVkeHUh?=
LAMA-84 NEDxdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O4VGlEPTB;ND6zNFQzOSEQvF2= MXvTRW5ITVJ?
LB373-MEL-D Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULlTGg3UUN3ME20MlM3Pzh7IN88US=> M{TqdXNCVkeHUh?=
UACC-257 NGHM[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon5TWM2OD12LkO5OVM1KM7:TR?= NXj0S|Y{W0GQR1XS
MC-CAR NEXYfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP5NlBKSzVyPUSuOFM6QSEQvF2= MUPTRW5ITVJ?
COLO-320-HSR M4fhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTRwNES0Nlch|ryP NGm4[5pUSU6JRWK=
P30-OHK MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L1[mlEPTB;ND62OlU5OSEQvF2= M4\je3NCVkeHUh?=
UACC-812 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqwTWM2OD12Lk[5NVYyKM7:TR?= NGK0flRUSU6JRWK=
CTB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLhRpB3UUN3ME20MlcyPTV3IN88US=> NUnxOZpXW0GQR1XS
ALL-PO MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGThc4xKSzVyPUSuPFQxPzdizszN MV3TRW5ITVJ?
SK-MEL-2 NUnLZ5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTMTWM2OD12Lki2PVU2KM7:TR?= NED3U3RUSU6JRWK=
TC-YIK MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof1TWM2OD12Lkm3PVQzKM7:TR?= MmXQV2FPT0WU
NCI-H1882 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OzWGlEPTB;NT6wNlAxOSEQvF2= NH3abnhUSU6JRWK=
MHH-CALL-2 NUm0T3hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jxeGlEPTB;NT6wOVA1OiEQvF2= NXPq[pJPW0GQR1XS
U-87-MG NECyXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTVwMEm0OlYh|ryP MorwV2FPT0WU
NCI-H1092 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorOTWM2OD13LkK2OVU2KM7:TR?= NEPjOlNUSU6JRWK=
TE-441-T NW\oTYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfvWYNmUUN3ME21MlI4QDJizszN MV\TRW5ITVJ?
SK-MEL-1 NXLYdlBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q4VmlEPTB;NT6yPVA1PCEQvF2= MmD1V2FPT0WU
EW-22 NV\TXog6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL3c4V4UUN3ME21MlI6PDZ4IN88US=> MnjpV2FPT0WU
MZ7-mel MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\OSJhGUUN3ME21MlQxPjlzIN88US=> M3e0OHNCVkeHUh?=
LP-1 NHTUNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTVwNEGyPVEh|ryP NYXlc3dnW0GQR1XS
NCI-SNU-16 NUHhTmNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX0TWM2OD13Lk[0NFc1KM7:TR?= MYnTRW5ITVJ?
LU-65 NUHZOJBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW0TWM2OD13Lke2N|c{KM7:TR?= MXPTRW5ITVJ?
CW-2 NXH3Rm43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\xTJRYUUN3ME21Mlg2QTV7IN88US=> MnPMV2FPT0WU
WSU-NHL NELTXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;aTWM2OD13Lkm1NVc1KM7:TR?= M3qwNHNCVkeHUh?=
IST-MES1 NF6zTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDqWoZWUUN3ME21Mlk2PDR|IN88US=> NXXEdVBNW0GQR1XS
U-266 M125eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG5VmpOUUN3ME21Mlk5OjB{IN88US=> M2XlTHNCVkeHUh?=
TALL-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTZwMUS2PFgh|ryP MlLtV2FPT0WU
Calu-6 M2fS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\6TWM2OD14LkG1N|E3KM7:TR?= MnriV2FPT0WU
MMAC-SF NWe5dZJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvacJJNUUN3ME22MlE5PTV4IN88US=> M{\FenNCVkeHUh?=
NCI-H82 NGewSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPtV4FsUUN3ME22MlIxPDh7IN88US=> Mn[5V2FPT0WU
RS4-11 NVvyNHpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvBPHFKSzVyPU[uNlU5QTdizszN M1LTOnNCVkeHUh?=
SNU-C2B Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr5OnJKSzVyPU[uOFA6PjlizszN NYH0V3dlW0GQR1XS
BOKU NFT2XYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXjUFBKSzVyPU[uOFc2QTdizszN NITzVWFUSU6JRWK=
C8166 NX76elFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KwbmlEPTB;Nj61OVkyOiEQvF2= MXPTRW5ITVJ?
D-247MG NECzNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4TWM2OD15LkC0N|Q4KM7:TR?= M13MN3NCVkeHUh?=
EW-18 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfvSndVUUN3ME23MlA4Ojl{IN88US=> NV;UPFEyW0GQR1XS
KG-1 NUPFRYg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jRTmlEPTB;Nz62Nlc{QCEQvF2= NELGT3BUSU6JRWK=
REH NHTBVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HVWmlEPTB;Nz62PFExQSEQvF2= M2noSHNCVkeHUh?=
U-698-M Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;XOlRmUUN3ME23Mlg1OzF3IN88US=> NFrNZnJUSU6JRWK=
KP-N-RT-BM-1 M{myXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvQbpJZUUN3ME23Mlk{ODJ7IN88US=> NHr2bYxUSU6JRWK=
MS-1 NEnRe3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD3XFFOUUN3ME23Mlk3ODRzIN88US=> MYXTRW5ITVJ?
SNU-C1 NFnHclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\HZVlzUUN3ME23Mlk5OTl{IN88US=> MoD2V2FPT0WU
SK-MM-2 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\0bWlEPTB;OD6yOlA3PSEQvF2= NFS0OGxUSU6JRWK=
LAN-6 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRThwM{CwNFEh|ryP MkW0V2FPT0WU
NEC8 NUDa[YljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLGTWM2OD16LkOwOlkyKM7:TR?= NI\Fd3pUSU6JRWK=
NCI-H1770 NXy1OlRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G5OGlEPTB;OD6zPFAxOiEQvF2= NIHWOGNUSU6JRWK=
D-336MG M2HCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRThwNECxNVYh|ryP MkXjV2FPT0WU
COLO-829 NIDxdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfaTWM2OD16LkS4PFc6KM7:TR?= NUC4XlFFW0GQR1XS
LS-513 NHX0fZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHpSohKSzVyPUiuOVk2QTlizszN MU\TRW5ITVJ?
YT MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TVb2lEPTB;OD62NlQzPyEQvF2= M{TUb3NCVkeHUh?=
EW-24 NXTTOnhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRThwN{[1OEDPxE1? NV;CXWNtW0GQR1XS
IST-SL1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRThwOE[1OFMh|ryP MmDtV2FPT0WU
CA46 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;FendtUUN3ME24Mlk2ODl6IN88US=> MX\TRW5ITVJ?
NCI-H1838 M3XTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVToVFF[UUN3ME24Mlk5PjB{IN88US=> MV;TRW5ITVJ?
NCI-H719 MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\YO3Z7UUN3ME25MlI2Ojd7IN88US=> M4XRT3NCVkeHUh?=
HCE-T NY\VRXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ZTWM2OD17LkOwPFUyKM7:TR?= MWXTRW5ITVJ?
A498 NGOyc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHGTWM2OD17LkO2NVI1KM7:TR?= MWrTRW5ITVJ?
LB831-BLC MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjTeplKSzVyPUmuO|Y2OjFizszN NHK4TIhUSU6JRWK=
SKM-1 NHHkUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXkNJhKSzVyPUmuPFU6PjNizszN NFPuRohUSU6JRWK=
THP-1 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTlwOU[5NVgh|ryP MU\TRW5ITVJ?
SHP-77 NFrzfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnFbmVoUUN3ME2xNE41ODdizszN NV3ZfGJWW0GQR1XS
EW-3 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFyLk[yPFkh|ryP MojBV2FPT0WU
KY821 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;qTWM2OD1zMD63OlMh|ryP MYLTRW5ITVJ?
NCI-SNU-1 NELlZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PtZWlEPTB;MUGuNFIyPyEQvF2= M16xOHNCVkeHUh?=
HCC2218 NI\2SYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LLR2lEPTB;MUGuN|k5PiEQvF2= Mo\iV2FPT0WU
IM-9 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFzLkWxNFYh|ryP M3njOXNCVkeHUh?=
NCI-H889 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFzLkWzNVMh|ryP Mkm3V2FPT0WU
HDLM-2 NUnpT4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm4RoFKSzVyPUGyMlQyPTlizszN NF7rc3FUSU6JRWK=
LB2518-MEL MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPpUoFKSzVyPUGyMlY5OTVizszN M1;pUXNCVkeHUh?=
NCI-H23 M4S2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrqNVJKSzVyPUGzMlI1OjVizszN Mo\KV2FPT0WU
NB17 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe3RnlJUUN3ME2xN{41PTd7IN88US=> NFL1UWdUSU6JRWK=
NCI-H322M MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXTTWM2OD1zND60NFY5KM7:TR?= MmnCV2FPT0WU
SUP-T1 NIHIb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCwTWM2OD1zND60NVMh|ryP MlXZV2FPT0WU
ES3 M4XGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfyRpRzUUN3ME2xOU4xPzB|IN88US=> NF72VoJUSU6JRWK=
ES5 M1jYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHQTWM2OD1zNT6wO|g4KM7:TR?= M17VNHNCVkeHUh?=
NCI-H1650 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF3LkS5O|kh|ryP NYXK[VdNW0GQR1XS
NCI-H226 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF3Lki3Olgh|ryP MWrTRW5ITVJ?
COR-L88 MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vTfGlEPTB;MU[uN|E1KM7:TR?= NETmSWJUSU6JRWK=
SCC-15 NX7kSYg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF4LkO4Olkh|ryP NYnvWZJrW0GQR1XS
GOTO NXGyTYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXBTWM2OD1zNj60O|k{KM7:TR?= M{jOc3NCVkeHUh?=
SIMA NWXueVBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnYVpFEUUN3ME2xOk41QDB{IN88US=> M1vudnNCVkeHUh?=
NCI-H1299 M{TYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\SfGlEPTB;MUeuNVU6OSEQvF2= MVTTRW5ITVJ?
NCI-H1581 NV3xWJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnJRWxKSzVyPUG3MlQzOTlizszN Ml;RV2FPT0WU
MHH-NB-11 NWLXO3pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHrbHBSUUN3ME2xO{46Pjh|IN88US=> NULhZYFQW0GQR1XS
MFM-223 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y4T2lEPTB;MUiuNFU{QCEQvF2= NV:3NZFKW0GQR1XS
ES7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES1RZhKSzVyPUG4MlU1OzFizszN MV\TRW5ITVJ?
JVM-3 NXXZbFY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF6LkexO{DPxE1? MUPTRW5ITVJ?
RL MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HTXWlEPTB;MkCuN|g5KM7:TR?= NIXndGNUSU6JRWK=
EC-GI-10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\yWGlEPTB;MkGuNlA1OSEQvF2= MnfFV2FPT0WU
LNCaP-Clone-FGC M1HHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTDdVBKSzVyPUKxMlY4PjhizszN MXrTRW5ITVJ?
IMR-5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fnfGlEPTB;MkGuPFQ6PCEQvF2= MWjTRW5ITVJ?
KP-N-YS Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\LTWM2OD1{MT64O|Uh|ryP NX;Vc3kxW0GQR1XS
Mo-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HYfmlEPTB;MkKuNlE5PSEQvF2= NVPkZZBHW0GQR1XS
NCI-H128 NGfCXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ|LkW4OVMh|ryP MX7TRW5ITVJ?
RH-1 NUD0eHl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml23TWM2OD1{Mz63PFY3KM7:TR?= MWDTRW5ITVJ?
NCI-H2171 MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH1TWM2OD1{ND6yOFg2KM7:TR?= M1HpeHNCVkeHUh?=
RPMI-8866 NYe1WXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PGcGlEPTB;Mk[uO|QzKM7:TR?= NH3pRYNUSU6JRWK=
SK-N-FI MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjZ[W1KSzVyPUK3MlM5OTFizszN NVvKNI5IW0GQR1XS
LOXIMVI Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\QV2lEPTB;MkeuPFA2OSEQvF2= NEDCbHJUSU6JRWK=
P31-FUJ NUTEPXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu5NIhtUUN3ME2zNU42Ozd2IN88US=> M1vObXNCVkeHUh?=
KMS-12-PE NH65blhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKxTWM2OD12OT61N|AzKM7:TR?= MljHV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID